Stocks and Investing Stocks and Investing
Fri, February 25, 2022

Matt Borsch Upgraded (AMED) to Buy and Held Target at $190 on, Feb 25th, 2022


Published on 2024-10-27 19:50:01 - WOPRAI, Matt Borsch
  Print publication without navigation


Matt Borsch of BMO Capital, Upgraded "Amedisys, Inc." (AMED) to Buy and Held Target at $190 on, Feb 25th, 2022.

Matt has made no other calls on AMED in the last 4 months.



There are 7 other peers that have a rating on AMED. Out of the 7 peers that are also analyzing AMED, 2 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whit Mayo of "SVB Leerink" Maintained at Hold with Increased Target to $147 on, Friday, February 18th, 2022
  • Scott Fidel of "Stephens & Co." Maintained at Hold with Increased Target to $185 on, Thursday, November 4th, 2021


These are the ratings of the 5 analyists that currently disagree with Matt


  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $175 on, Thursday, February 24th, 2022
  • Steve Valiquette of "Barclays" Maintained at Buy with Decreased Target to $213 on, Tuesday, December 21st, 2021
  • John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $225 on, Monday, November 8th, 2021
  • Jonathan Yong of "Credit Suisse" Maintained at Buy with Increased Target to $205 on, Thursday, November 4th, 2021
  • Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $221 on, Thursday, November 4th, 2021

Contributing Sources